Evidence map›Paper›PMID 27208380›Full record

SynthesisDiabetes care2016

Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis.

Marta Guasch-Ferré, Adela Hruby, Estefanía Toledo, Clary B Clish, Miguel A Martínez-González, Jordi Salas-Salvadó, Frank B Hu

Registry-linked trialOpen access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06959043 (Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes), which is not on this map. Cited by 537 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
537citing papers in PubMed, 9 pooled it
36.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06959043 narecruitingnot on this mapstarted 2022, after this paper: background citation

Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes: Plant-based Diet and Physical Exercise

TypeinterventionalSponsorMaria Elizabeth Rossi da SilvaRan2022 to 2026Enrolled60ConditionsType 2 Diabetes Mellitus (T2DM), Insulin Resistance, Inflamation, Gut MicrobiomesArmsProbiotic Supplementation, Placebo Administration
3 · Its place in the literature

Who cites it

537 citing papers in PubMed, 9 syntheses or guidelines pooled it, 908 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Nutrients · 2024
    Trial
  15. Trial
  16. Review
  17. Gut microbes · 2026
    Article
  18. Article
  19. Review
  20. Article

477 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Marta Guasch-FerréDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili Institute for Health Research, Rovira i Virgili University, Reus, Spain CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-8525-1404
Adela HrubyDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Estefanía ToledoCIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain Department of Preventive Medicine and Public Health, University of Navarra, Health Research Institute of Navarra, Pamplona, Spain.
Clary B ClishBroad Institute, Cambridge, MA.
Miguel A Martínez-GonzálezCIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain Department of Preventive Medicine and Public Health, University of Navarra, Health Research Institute of Navarra, Pamplona, Spain.
Jordi Salas-SalvadóHuman Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili Institute for Health Research, Rovira i Virgili University, Reus, Spain CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-2700-7459
Frank B HuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA nhbfh@channing.harvard.edu.
Instituto de Salud Carlos III · ESHarvard University · USBrigham and Women's Hospital · USBroad Institute · US

Funding

Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI CORKEY, BARBARA E. · 1992 to 2021
$25.0M
DIETARY PATTERNS AND RISK OF CARDIOVASCULAR DISEASER01HL060712 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HU, FRANK B, QI, QIBIN · 1998 to 2021
$8.0M
Mediterranean diet, Metabolites, and Cardiovascular DiseaseR01HL118264 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI HU, FRANK B, LAMUELA-RAVENTÓS, ROSA · 2013 to 2025
$6.8M
Dietary Interventions, Metabolites, and Risk of Type 2 DiabetesR01DK102896 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI HU, FRANK B, MARTINEZ GONZALEZ, MIGUEL A. · 2014 to 2017
$1.9M
NHLBI NIH HHS R01 HL060712NHLBI NIH HHS R01 HL118264NIDDK NIH HHS P30 DK046200NIDDK NIH HHS R01 DK102896
6 · The paper itself

Abstract

objectiveTo conduct a systematic review of cross-sectional and prospective human studies evaluating metabolite markers identified using high-throughput metabolomics techniques on prediabetes and type 2 diabetes. RESEARCH DESIGN AND

methodsWe searched MEDLINE and EMBASE databases through August 2015. We conducted a qualitative review of cross-sectional and prospective studies. Additionally, meta-analyses of metabolite markers, with data estimates from at least three prospective studies, and type 2 diabetes risk were conducted, and multivariable-adjusted relative risks of type 2 diabetes were calculated per study-specific SD difference in a given metabolite.

resultsWe identified 27 cross-sectional and 19 prospective publications reporting associations of metabolites and prediabetes and/or type 2 diabetes. Carbohydrate (glucose and fructose), lipid (phospholipids, sphingomyelins, and triglycerides), and amino acid (branched-chain amino acids, aromatic amino acids, glycine, and glutamine) metabolites were higher in individuals with type 2 diabetes compared with control subjects. Prospective studies provided evidence that blood concentrations of several metabolites, including hexoses, branched-chain amino acids, aromatic amino acids, phospholipids, and triglycerides, were associated with the incidence of prediabetes and type 2 diabetes. We meta-analyzed results from eight prospective studies that reported risk estimates for metabolites and type 2 diabetes, including 8,000 individuals of whom 1,940 had type 2 diabetes. We found 36% higher risk of type 2 diabetes per study-specific SD difference for isoleucine (pooled relative risk 1.36 [1.24-1.48]; I(2) = 9.5%), 36% for leucine (1.36 [1.17-1.58]; I(2) = 37.4%), 35% for valine (1.35 [1.19-1.53]; I(2) = 45.8%), 36% for tyrosine (1.36 [1.19-1.55]; I(2) = 51.6%), and 26% for phenylalanine (1.26 [1.10-1.44]; I(2) = 56%). Glycine and glutamine were inversely associated with type 2 diabetes risk (0.89 [0.81-0.96] and 0.85 [0.82-0.89], respectively; both I(2) = 0.0%).

conclusionsIn studies using high-throughput metabolomics, several blood amino acids appear to be consistently associated with the risk of developing type 2 diabetes.

Indexed as

BiomarkersCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansIncidenceMetabolomicsMiddle AgedPrediabetic StateProspective StudiesBiomarkers

Identifiers

PMID27208380
PMCPMC4839172
OpenAlexW2338627428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.